Stirred tank bioreactors in vaccine development - Producing AAV particles and COVID-19 spike-proteins in suspension culture

Vaccines are essential tools for resisting pathogens and controlling global pandemics. Various types of virus vaccines, such as live attenuated, inactivated pathogen and subunit vaccines have been widely produced using mammalian cell cultures. However, they often rely on attachment cell culture. For higher production capacity, increased yield, and most importantly, ease of production scale-up, it is more desirable to produce vaccines in suspension cell culture platforms. The widely available suspension bioreactors used in antibody production will allow a faster development process of versatile vaccine platforms. Novel technologies such as mRNA vaccines, Adeno virus vector and Adeno-associated virus (AAV) vector-based vaccines have all played a key role in controlling the recent COVID-19 pandemic. Especially cell culture produced AAV vectors have gained momentum as one of the most effective gene & protein delivery tools in vaccine production as well as gene therapy. In this webinar, an expert in Cell & Gene Therapy by Eppendorf will highlight the potential and benefits of stirred-tank bioreactors in the production of AAV viral particles and SARS-CoV-2 S HexaPro spike protein using a suspension-adapted HEK293 cell line platform (Expi293F). He will share his technical experience on how they have developed both processes in 1 L bioreactors controlled by the parallel bioreactor control system SciVario® twin.

 

Learning Objectives